Second Sight Medical Products Inc EYES shares soared Thursday after the company said two newly approved surgical centers in Italy had performed their first commercial implants of the company's retina prosthesis.
The medical device company changed hands recently at $19.11, up nearly 28 percent.
About 100 commercial operations have been performed using the product to date worldwide in patients suffering from outer retinal degeneration.
The product, Argus II, is available in 11 countries including the U.S. and much of Europe.
"We are thrilled to see the expanded availability of Argus II in Italy," Chief Executive Robert Greenberg said.
Second Sight went public in November and until recently had fallen sharply. Shares are up more than 95 percent in the past month.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
